{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:37:30Z","timestamp":1783489050549,"version":"3.55.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T00:00:00Z","timestamp":1551916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP17lk0201063"],"award-info":[{"award-number":["JP17lk0201063"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Extramammary Paget's disease (EMPD) is a rare cutaneous adenocarcinoma that clinicopathologically resembles breast cancer. The prognosis of metastatic EMPD is poor. Although several chemotherapies have been tried, the effects are temporary; better drugs and combinations are required.<\/jats:p>\n               <jats:p>In the present study, we retrospectively analyze the efficacy and safety of combination of cisplatin, epirubicin, and paclitaxel in five metastatic EMPD cases. The efficacy was better than that for previously reported regimens: 80% partial responses, including two patients who were refractory to taxane- and\/or platinum-based regimens. In terms of safety, four patients who were able to continue treatment exhibited acceptable tolerability.<\/jats:p>\n               <jats:p>This is the first regimen to combine taxane and anthracycline. When treating breast cancer, anthracycline is regarded as the key cytotoxic agent, and anthracycline in combination with taxane constitutes a key chemotherapeutic regimen. Given our results, we speculate both drugs are critical chemotherapeutic agents for the treatment of metastatic EMPD.<\/jats:p>","DOI":"10.1634\/theoncologist.2018-0856","type":"journal-article","created":{"date-parts":[[2019,3,7]],"date-time":"2019-03-07T19:55:22Z","timestamp":1551988522000},"page":"e394-e396","source":"Crossref","is-referenced-by-count":27,"title":["Combination Cisplatin-Epirubicin-Paclitaxel Therapy for Metastatic Extramammary Paget's Disease"],"prefix":"10.1093","volume":"24","author":[{"given":"Ikuko","family":"Hirai","sequence":"first","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiji","family":"Tanese","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshio","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maki","family":"Ishii","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Department of Cellular Signaling, Institute for Advanced Medical Research, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeru","family":"Funakoshi","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Keio University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,3,7]]},"reference":[{"key":"2021122507122212200_R1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/his.13239","article-title":"Molecular subtyping of mammary-like adenocarcinoma of the vulva shows molecular similarity to breast carcinomas","volume":"71","author":"Tessier-Cloutier","year":"2017","journal-title":"Histopathology"},{"key":"2021122507122212200_R2","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.jdermsci.2016.06.004","article-title":"Proposal for a TNM staging system for extramammary Paget disease: Retrospective analysis of 301 patients with invasive primary tumors","volume":"83","author":"Ohara","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2021122507122212200_R3","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s10147-014-0686-2","article-title":"Combination chemotherapy of low-dose 5-fluorouracil and cisplatin for advanced extramammary Paget's disease","volume":"20","author":"Tokuda","year":"2015","journal-title":"Int J Clin Oncol"},{"key":"2021122507122212200_R4","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1111\/bjd.12788","article-title":"Combination chemotherapy for metastatic extramammary Paget disease","volume":"170","author":"Oashi","year":"2014","journal-title":"Br J Dermatol"},{"key":"2021122507122212200_R5","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/1346-8138.13200","article-title":"Usefulness of docetaxel as first-line chemotherapy for metastatic extramammary Paget's disease","volume":"43","author":"Yoshino","year":"2016","journal-title":"J Dermatol"},{"key":"2021122507122212200_R6","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1111\/j.1346-8138.2010.01149.x","article-title":"Successful treatment of metastatic extramammary Paget's disease with S-1 and docetaxel combination chemotherapy","volume":"38","author":"Matsushita","year":"2011","journal-title":"J Dermatol"},{"key":"2021122507122212200_R7","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1023\/A:1006429205363","article-title":"Cisplatin-epirubicin-paclitaxel weekly administration with G-CSF support in advanced breast cancer. A Southern Italy Cooperative Oncology Group (SICOG) phase II study","volume":"62","author":"Frasci","year":"2000","journal-title":"Breast Cancer Res Treat"},{"key":"2021122507122212200_R8","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1111\/1346-8138.13869","article-title":"Modified weekly regimen of cisplatin, epirubicin and paclitaxel induced a durable response in two cases of metastatic extramammary Paget's disease","volume":"44","author":"Hirai","year":"2017","journal-title":"J Dermatol"},{"key":"2021122507122212200_R9","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1200\/JCO.1998.16.10.3439","article-title":"Cytotoxic and hormonal treatment for metastatic breast cancer: A systematic review of published randomized trials involving 31,510 women","volume":"16","author":"Fossati","year":"1998","journal-title":"J Clin Oncol"},{"key":"2021122507122212200_R10","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1200\/JCO.2007.11.3787","article-title":"Taxane-based combinations as adjuvant chemotherapy of early breast cancer: A meta-analysis of randomized trials","volume":"26","author":"De Laurentiis","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2018-0856","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2018-0856","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/e394\/41918481\/oncolo_24_6_e394.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/24\/6\/e394\/41918481\/oncolo_24_6_e394.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T07:13:14Z","timestamp":1640416394000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/24\/6\/e394\/6439251"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,7]]},"references-count":10,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,3,7]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2018-0856","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6,1]]},"published":{"date-parts":[[2019,3,7]]}}}